Casi Pharmaceuticals Inc (CASI)

$1.29 -0.01 (-0.77%)
Market Cap 15.87M
Revenue (ttm) 28.54M
Net Income (ttm) -39.26M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -137.56%
Debt to Equity Ratio -2.29
Volume 14,200
Avg Vol 156,682
Day's Range N/A - N/A
Shares Out 12.30M
Stochastic %K 13%
Beta 0.63
Analysts Strong Sell
Price Target $4.00

Company Profile

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company's hematology/oncology assets in pipeline include CNCT19, an autologous CD19 CAR-T investiga...

Industry: Biotechnology
Sector: Healthcare
Phone: 86 10 6508 6063
Address:
1701-1702, China Central Office Tower 1, No. 81 Jianguo Road Chaoyang District, Beijing, China
Stock_Catcher
Stock_Catcher Jul. 29 at 12:25 PM
$CASI thin
0 · Reply
Abdul92z
Abdul92z Jul. 28 at 6:18 PM
Watch $CASI above 1.75 and $CRDL above 1.56
0 · Reply
Abdul92z
Abdul92z Jul. 26 at 10:17 PM
$CASI watch it above 1.57
0 · Reply
Gmblr777
Gmblr777 Jun. 30 at 2:21 PM
$CASI this stock is so trash
0 · Reply
Gmblr777
Gmblr777 Jun. 27 at 7:54 PM
$CASI eh 🥲
0 · Reply
Gmblr777
Gmblr777 Jun. 24 at 8:01 PM
$CASI good bounce back 👌🏼
0 · Reply
hdl222
hdl222 Jun. 20 at 9:34 AM
$CASI lets gooo
0 · Reply
PenkeTrading
PenkeTrading Jun. 19 at 1:11 PM
I found you an Oversold RSI (Relative Strength Index) on the daily chart of CASI Pharmaceuticals Inc. Is that bullish or bearish? $CASI #CASI #RsiOversold #NASDAQ
0 · Reply
Gmblr777
Gmblr777 Jun. 18 at 9:54 PM
$CASI who is buying?🚀🚀
0 · Reply
nsosis
nsosis Jun. 17 at 6:13 PM
$CASI anybody here holding ah?
0 · Reply
Latest News on CASI
CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program

Jul 21, 2025, 4:05 PM EDT - 13 days ago

CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program

CASI Pharmaceuticals Provides Business and Clinical Update

May 19, 2025, 9:00 AM EDT - 2 months ago

CASI Pharmaceuticals Provides Business and Clinical Update

CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results

May 16, 2025, 8:00 AM EDT - 2 months ago

CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results

CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China

May 12, 2025, 8:00 AM EDT - 2 months ago

CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China

CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement

May 7, 2025, 8:00 AM EDT - 3 months ago

CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement

CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company

Apr 3, 2025, 8:00 AM EDT - 4 months ago

CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company

CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results

Mar 31, 2025, 8:15 AM EDT - 4 months ago

CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results

CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia

Jan 6, 2025, 8:00 AM EST - 7 months ago

CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia

CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results

Nov 15, 2024, 8:00 AM EST - 9 months ago

CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results

CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia

Oct 24, 2024, 8:00 AM EDT - 10 months ago

CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia

CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE

Sep 4, 2024, 8:00 AM EDT - 11 months ago

CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS

Aug 16, 2024, 8:00 AM EDT - 1 year ago

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS

CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS

Jul 19, 2024, 5:30 PM EDT - 1 year ago

CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS

CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP

Jul 8, 2024, 7:30 AM EDT - 1 year ago

CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP

CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company

Jun 26, 2024, 4:15 PM EDT - 1 year ago

CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company

CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He

Jun 26, 2024, 4:10 PM EDT - 1 year ago

CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He

CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)

May 15, 2024, 8:00 AM EDT - 1 year ago

CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS

May 14, 2024, 8:00 AM EDT - 1 year ago

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS

Mar 28, 2024, 7:00 AM EDT - 1 year ago

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS

CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China

Mar 5, 2024, 7:00 AM EST - 1 year ago

CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China

CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA

Feb 16, 2024, 7:00 AM EST - 1 year ago

CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA

CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

Nov 14, 2023, 7:00 AM EST - 1 year ago

CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA

Nov 8, 2023, 7:00 AM EST - 1 year ago

CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

Aug 11, 2023, 7:00 AM EDT - 2 years ago

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals

Aug 1, 2023, 7:00 AM EDT - 2 years ago

Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals

CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339

Jul 20, 2023, 8:00 AM EDT - 2 years ago

CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339

Cleave Therapeutics Announces Acquisition of Clinical and Preclinical Assets

Jul 20, 2023, 8:00 AM EDT - 2 years ago

Cleave Therapeutics Announces Acquisition of Clinical and Preclinical Assets

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS

May 17, 2023, 7:35 AM EDT - 2 years ago

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS

CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022

Apr 26, 2023, 9:49 AM EDT - 2 years ago

CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS

Apr 26, 2023, 7:00 AM EDT - 2 years ago

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS

CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGER

Mar 21, 2023, 4:30 PM EDT - 2 years ago

CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGER

Casi Pharmaceuticals to run clinical trial for multiple myeloma drug in China

Jan 6, 2023, 8:42 AM EST - 2 years ago

Casi Pharmaceuticals to run clinical trial for multiple myeloma drug in China

CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA

Jan 6, 2023, 7:00 AM EST - 2 years ago

CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA

CASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION

Dec 15, 2022, 7:00 AM EST - 2 years ago

CASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION

CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS

Nov 14, 2022, 7:00 AM EST - 2 years ago

CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS

CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEET

Sep 23, 2022, 7:00 AM EDT - 3 years ago

CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEET

ALJ Regional Hldgs (NASDAQ:ALJJ), CASI Pharmaceuticals (NASDAQ:CASI) – $2.2 Million Bet On Terns Pharmaceuticals? Check Out These 4 Penny Stocks Insiders Are Buying

Sep 9, 2022, 10:32 AM EDT - 3 years ago

ALJ Regional Hldgs (NASDAQ:ALJJ), CASI Pharmaceuticals (NASDAQ:CASI) – $2.2 Million Bet On Terns Pharmaceuticals? Check Out These 4 Penny Stocks Insiders Are Buying

LDI TERN

CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE DOSING OF FIRST PATIENT IN BI-1206 PHASE 1 CLINICAL TRIAL FOR THE TREATMENT OF RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMA IN CHINA

Sep 7, 2022, 7:00 AM EDT - 3 years ago

CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE DOSING OF FIRST PATIENT IN BI-1206 PHASE 1 CLINICAL TRIAL FOR THE TREATMENT OF RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMA IN CHINA

CASI Pharmaceuticals And 2 Other Stocks Under $4 Insiders Are Aggressively Buying

Aug 29, 2022, 8:58 AM EDT - 3 years ago

CASI Pharmaceuticals And 2 Other Stocks Under $4 Insiders Are Aggressively Buying

HCWB HSDT

CASI Pharmaceuticals, Inc. (CASI) CEO Wei-Wu He on Q2 2022 Results - Earnings Call Transcript

Aug 12, 2022, 12:28 PM EDT - 3 years ago

CASI Pharmaceuticals, Inc. (CASI) CEO Wei-Wu He on Q2 2022 Results - Earnings Call Transcript

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS

Aug 12, 2022, 7:00 AM EDT - 3 years ago

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS

CASI PHARMACEUTICALS TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL AUGUST 12, 2022

Aug 5, 2022, 8:38 AM EDT - 3 years ago

CASI PHARMACEUTICALS TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL AUGUST 12, 2022

CASI PHARMACEUTICALS ANNOUNCES ITS PARTNER, PRECISION AUTOIMMUNE THERAPEUTICS CO., LTD HAS COMPLETED FIRST-ROUND FINANCING OF $21 MILLION

Jul 8, 2022, 7:00 AM EDT - 3 years ago

CASI PHARMACEUTICALS ANNOUNCES ITS PARTNER, PRECISION AUTOIMMUNE THERAPEUTICS CO., LTD HAS COMPLETED FIRST-ROUND FINANCING OF $21 MILLION

CASI Pharmaceuticals stock falls after reverse split takes effect

Jun 2, 2022, 6:34 AM EDT - 3 years ago

CASI Pharmaceuticals stock falls after reverse split takes effect

CASI PHARMACEUTICALS ANNOUNCES REVERSE STOCK SPLIT

May 26, 2022, 4:30 PM EDT - 3 years ago

CASI PHARMACEUTICALS ANNOUNCES REVERSE STOCK SPLIT

CASI PHARMACEUTICALS ENTERES INTO SUBLICENSE AGREEMENT WITH TIANSHI PHARMACEUTICALS FOR ANTI-CD38 MONOCLONAL ANTIBODY (MAB) CID-103 IN AUTOIMMUNE FIELD

May 24, 2022, 7:00 AM EDT - 3 years ago

CASI PHARMACEUTICALS ENTERES INTO SUBLICENSE AGREEMENT WITH TIANSHI PHARMACEUTICALS FOR ANTI-CD38 MONOCLONAL ANTIBODY (MAB) CID-103 IN AUTOIMMUNE FIELD

CASI Pharmaceuticals, Inc.'s (CASI) CEO Wei-Wu He on Q1 2022 Results - Earnings Call Transcript

May 12, 2022, 11:32 AM EDT - 3 years ago

CASI Pharmaceuticals, Inc.'s (CASI) CEO Wei-Wu He on Q1 2022 Results - Earnings Call Transcript

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS

May 12, 2022, 7:00 AM EDT - 3 years ago

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS

CASI PHARMACEUTICALS TO REPORT FIRST QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL MAY 12, 2022

May 2, 2022, 7:00 AM EDT - 3 years ago

CASI PHARMACEUTICALS TO REPORT FIRST QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL MAY 12, 2022

Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework

Apr 1, 2022, 2:31 PM EDT - 3 years ago

Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework

ONC HCM ZLAB

Stock_Catcher
Stock_Catcher Jul. 29 at 12:25 PM
$CASI thin
0 · Reply
Abdul92z
Abdul92z Jul. 28 at 6:18 PM
Watch $CASI above 1.75 and $CRDL above 1.56
0 · Reply
Abdul92z
Abdul92z Jul. 26 at 10:17 PM
$CASI watch it above 1.57
0 · Reply
Gmblr777
Gmblr777 Jun. 30 at 2:21 PM
$CASI this stock is so trash
0 · Reply
Gmblr777
Gmblr777 Jun. 27 at 7:54 PM
$CASI eh 🥲
0 · Reply
Gmblr777
Gmblr777 Jun. 24 at 8:01 PM
$CASI good bounce back 👌🏼
0 · Reply
hdl222
hdl222 Jun. 20 at 9:34 AM
$CASI lets gooo
0 · Reply
PenkeTrading
PenkeTrading Jun. 19 at 1:11 PM
I found you an Oversold RSI (Relative Strength Index) on the daily chart of CASI Pharmaceuticals Inc. Is that bullish or bearish? $CASI #CASI #RsiOversold #NASDAQ
0 · Reply
Gmblr777
Gmblr777 Jun. 18 at 9:54 PM
$CASI who is buying?🚀🚀
0 · Reply
nsosis
nsosis Jun. 17 at 6:13 PM
$CASI anybody here holding ah?
0 · Reply
RollingDollars
RollingDollars Jun. 17 at 5:41 PM
$CASI
0 · Reply
RollingDollars
RollingDollars Jun. 17 at 4:55 PM
$CASI .
0 · Reply
V9RDPUMA
V9RDPUMA Jun. 13 at 4:52 PM
$CASI Microcap biotech, needs cash, no news. We all know what this is...run up into a dilution offering.
0 · Reply
Swagg
Swagg Jun. 13 at 4:31 PM
$CASI Just a little "Shake 'N Bake" action going on here. KEEP BUYING
0 · Reply
alecsalaur198
alecsalaur198 Jun. 13 at 3:57 PM
$CASI extreme volatility
0 · Reply
Iftekharstock
Iftekharstock Jun. 13 at 3:55 PM
$CASI killed everyone 🤒
0 · Reply
_www_larval_com_
_www_larval_com_ Jun. 13 at 3:47 PM
$CASI just reverted -9% lower to 18% (~2Mv) a few minutes ago, 06/20 options, follow for more volatility.
0 · Reply
Iftekharstock
Iftekharstock Jun. 13 at 3:47 PM
$CASI fuck the retails👹👹👹
0 · Reply
makedatbread88
makedatbread88 Jun. 13 at 3:44 PM
$CASI just insane volume has to be more to the story here Buy out? Partnership? Something is up this volume isn’t retail
0 · Reply
Aloha98
Aloha98 Jun. 13 at 3:32 PM
$CASI let s gooo 🔜5️⃣🫶😍
0 · Reply
DaBullRunner
DaBullRunner Jun. 13 at 3:26 PM
$CGTL looks like it’s ready to revisit HOD $EONR adding these dips as the energy tickers are hot and this one has that aura $HUSA $USEG Reminds me of BURU with a strong following $CASI watching
1 · Reply
Dojacay
Dojacay Jun. 13 at 3:22 PM
$CASI 3.5$ today
0 · Reply